ReviewBiomacromolecules2017
Enhancing Tumor Penetration of Nanomedicines.
Review in Biomacromolecules, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- Multifunctional Nanoparticles Fabricated by Dispersion Polymerization for the Treatment of Triple-Negative Breast Cancer.Journal of biomedical nanotechnology · 2026Article
- Biophysical Characterization of an Engineered CD80 Variant for CTLA-4 Blockade in Cancer Immunotherapy.The protein journal · 2026Article
- Multifunctional vesicles in cancer therapy and theranostics: current advances and future challenges.Journal of nanobiotechnology · 2025Review
- Advancing cancer radiotherapy: Harnessing radiosensitizers and nanotechnology for enhanced tumor control.International journal of pharmaceutics: X · 2025Review
- Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities.Drug delivery and translational research · 2025Review
- Nanotherapy for Neural Retinal Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic Index.Cancers · 2025Review
- Multi-Response Au-Nanohybrid Composite Triggered NIR-Light for Effective Anti-Tumor Therapy in Animal Model.International journal of nanomedicine · 2025Article
- Charge-Stabilized Nanodiscs as a New Class of Lipid Nanoparticles.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Emergence and impact of theranostic-nanoformulation of triple therapeutics for combination cancer therapy.Smart medicine · 2024Review
- Advances on Delivery System of Active Ingredients of Dried Toad Skin and Toad Venom.International journal of nanomedicine · 2024Review
- Multistage Self-Assembled Nanomaterials for Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2023Review
- Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25.Microbial cell factories · 2023Article
- Multidisciplinary strategies to enhance therapeutic effects of flavonoids from Epimedii Folium: Integration of herbal medicine, enzyme engineering, and nanotechnology.Journal of pharmaceutical analysis · 2023Review
- Extracellular matrix physical properties govern the diffusion of nanoparticles in tumor microenvironment.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Artificial and Naturally Derived Phospholipidic Bilayers as Smart Coatings of Solid-State Nanoparticles: Current Works and Perspectives in Cancer Therapy.International journal of molecular sciences · 2022Review
- Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system.Journal of nanobiotechnology · 2022Review
- Engineering prodrug nanomicelles as pyroptosis inducer for codelivery of PI3K/mTOR and CDK inhibitors to enhance antitumor immunity.Acta pharmaceutica Sinica. B · 2022Article
- Nanomedicine Penetration to Tumor: Challenges, and Advanced Strategies to Tackle This Issue.Cancers · 2022Review
- Calcium Enabled Remote Loading of a Weak Acid Into pH-sensitive Liposomes and Augmented Cytosolic Delivery to Cancer Cells via the Proton Sponge Effect.Pharmaceutical research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tumor-targeted nanomedicines have been extensively applied to alter the drawbacks and enhance the efficacy of chemotherapeutics. Despite the large number of preclinical nanomedicine studies showing initial success, their therapeutic benefit in the clinic has been rather modest, which is partially due to the inefficient tumor penetration caused by the tumor microenvironment (high density of cells and extracellular matrix, increased interstitial fluid pressure). Furthermore, tumor penetration of nanomedicines is significantly influenced by physicochemical characteristics, such as size, surface chemistry, and shape. The effect of size on tumor penetration has been exploited to design nanomedicines with switchable size to tackle this challenge. Moreover, several pharmacological and physical approaches have been developed to enhance the tumor penetration of nanomedicines, by penetration-promoting ligands, intratumoral drug release, and modulating the tumor microenvironment and vasculature. Overall, these efforts have resulted in nanomedicines with better tumor penetration properties and with enhanced therapeutic efficacy. Future research should be directed to penetration-promoting strategies with broad applicability and with high translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.